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Anemia can contribute to chronic allograft injury by limiting
oxygen delivery to tissues, particularly in the
tubulointerstitium. To determine mechanisms by which
erythropoietin (EPO) prevents chronic allograft injury we
utilized a rat model of full MHC-mismatched kidney
transplantation (Wistar Furth donor and Lewis recipients)
with removal of the native kidneys. EPO treatment entirely
corrected post-transplant anemia. Control rats developed
progressive proteinuria and graft dysfunction,
tubulointerstitial damage, inflammatory cell infiltration, and
glomerulosclerosis, all prevented by EPO. Normalization of
post-transplant hemoglobin levels by blood transfusions,
however, had no impact on chronic allograft injury,
indicating that EPO-mediated graft protection went beyond
the correction of anemia. Compared to syngeneic grafts,
control allografts had loss of peritubular capillaries, higher
tubular apoptosis, tubular and glomerular oxidative injury,
and reduced expression of podocyte nephrin; all prevented
by EPO treatment. The effects of EPO were associated with
preservation of intragraft expression of angiogenic factors,
upregulation of the anti-apoptotic factor p-Akt in tubuli, and
increased expression of Bcl-2. Inhibition of p-Akt by
Wortmannin partially antagonized the effect of EPO on
allograft injury and tubular apoptosis, and prevented
EPO-induced Bcl-2 upregulation. Thus non-erythropoietic
derivatives of EPO may be useful to prevent chronic renal
allograft injury.
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Despite the availability of better immunosuppressive proto-
cols, long-term results of kidney transplantation have not
improved much over the past 10 years because of progressive
allograft dysfunction, now indicated as ‘chronic allograft
injury’ (CAI), which results in an annual rate of graft loss
of 3–5%.1,2
Alloantigen-dependent and -independent factors have
both been found to have a role in allograft dysfunction,
which is normally preceded by hypertension and increased
urinary protein excretion.3 Tubular atrophy, interstitial
fibrosis with variable degree of inflammatory cell infiltration,
fibrointimal thickening of arteries and arterioles, and
glomerulosclerosis1,3 are all found in kidney biopsies from
transplant patients with CAI. No effective treatment exists
for CAI.3
Post-transplant anemia is a common problem in renal
transplant recipients and affects 30–60% of patients4
irrespective of the time from transplantation. Allograft
dysfunction, suppression of bone marrow erythropoiesis by
immunosuppressive drugs, and infections may cause post-
transplant anemia.4 Recent studies supported a negative
impact of anemia on kidney transplant outcome. In kidney-
transplanted patients, anemia at baseline significantly pre-
dicted mortality and graft failure over a 4-year follow-up.5
Another study in more than 1000 patients found that being
anemic 3 months after transplantation was associated with
increased renal allograft loss.6
Anemia can contribute to CAI by limiting oxygen delivery
to tissues, particularly to tubulointerstitium.7,8 In rat models
of chronic cyclosporine nephropathy and renal mass reduc-
tion,9,10 treatment with erythropoietin (EPO) increased
hematocrit, reduced tubulointerstitial damage, and preserved
tubular cells from apoptosis and oxidative injury.9,11 Clinical
studies in chronic kidney diseases other than transplantation
also found that correction of severe anemia with EPO slowed
glomerular filtration rate decline or reduced the risk of end-
stage renal disease.12–14 However, in another study, EPO
administration had no impact on glomerular filtration rate
decline.15 There is a paucity of data on EPO in human solid
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2012 International Society of Nephrology
Received 7 June 2010; revised 31 October 2011; accepted 8 November
2011; published online 8 February 2012
Correspondence: Marina Noris, Transplant Research Center, ‘Chiara Cucchi
De Alessandri & Gilberto Crespi’, Mario Negri Institute for Pharmacological
Research, Via Camozzi 3, Ranica 24020, Italy. E-mail: noris@marionegri.it
4These authors contributed equally to this work.
Kidney International (2012) 81, 903–918 903
organ transplantation. In a retrospective study in kidney
transplant patients with chronic allograft dysfunction, it was
found that the start of EPO treatment was associated with a
deceleration in the rate of graft function loss.16 On the other
hand, other studies failed to find any effect of EPO on graft
function.17,18
On the other hand, there are several experimental data
documenting the direct (erythropoiesis-independent) tissue-
protective effects of EPO that have been attributed to its
antiapoptotic, antioxidant, and angiogenic properties.19 In
puromycin-induced nephritic rats20 and in mice with anti-
glomerular antibody-induced glomerulonephritis,21 EPO
treatment ameliorated podocyte injury and decreased
proteinuria by a direct protective effect against apoptosis
and nephrin loss.20,21 However, the renoprotective properties
of EPO are not universal findings, as in other experimental
studies EPO was ineffective or even worsened glomerular
injury, possibly by aggravating systemic and glomerular
hypertension.22–24
Using a rat model of CAI in which progressive renal
damage mirrors the corresponding human condition,25
we designed a study aimed (1) to evaluate whether
EPO supplementation prevented CAI, and (2) to assess
the mechanism(s) underlying the EPO renoprotective
effects.
RESULTS
Experimental design
Orthotopic kidney transplantation was performed as
reported26 (Supplementary Methods online), using the fully
major histocompatibility complex class I and II incompatible
combination of Wistar Furth (WF, RT1u) as donors and
Lewis rats (LW, RT1l) as recipients. The recipient native
kidneys were removed.
Study 1. Allograft recipients received cyclosporine A
(5 mg/kg per day intramuscularly; Novartis Pharma) for the
first 10 days post transplant to prevent early acute rejection.25
Animals (Figure 1) were given either saline (control, n¼ 12)
or mouse EPO (EPO, 30 mg/kg subcutaneous loading dose
followed by 2.5 mg/kg weekly, n¼ 12). EPO dose was
adjusted weekly to maintain blood hemoglobin concentra-
tion within the normal range (14–17 g/dl). An additional
group (n¼ 12) underwent LW-to-LW syngeneic kidney
transplant. Three animals in each group were killed 21
days post transplant, and the others were followed up for
180 days. In the latter animals, blood hemoglobin was
monitored by microanalysis (capilette and Reflotron Plus,
Roche) weekly during the first month and then once a
month. Systolic blood pressure, evaluated in the conscious
rats by the tail-cuff method, serum creatinine (capilette and
Reflotron Plus), and 24-hour urinary protein excretion were
measured monthly, and 24-hour albuminuria was measured
120 days post transplant (immunoassay kits Nephrat,
Exocell).
At 21 or 180 days, animals were killed and the kidney graft
processed for immunohistology and real-time polymerase
chain reaction.
Study 2. Two groups of rats received a kidney allograft
and cyclosporine A as mentioned above, and were either left
untreated (control 2, n¼ 15) or given blood transfusions
(1–2 ml each, transfusion, n¼ 14) from LW rats with a
frequency targeted to maintain normal post-transplant
hemoglobin levels (target 14–17 g/dl), until the time of killing
at 180 days (Figure 1).
Study 3. Four additional groups of rats (n¼ 5 each)
received a kidney allograft and were untreated (control 3) or
treated with EPO (EPO3), or the inhibitor of Akt-
phosphorylation (p-Akt), Wortmannin27 (0.7 mg/kg weekly
from the transplant day, WT), or with EPOþWortmannin
(EPO/WT) until the time of killing at 180 days. In
preliminary experiments in naive LW rats, we found that
this dose of WT completely prevented the EPO-induced
upregulation of p-Akt in kidney tubuli (p-Aktþ tubuli: naive
51.7±0.2%; EPO: 72.3±11.5%; EPO/WT: 41.7±3.6%; WT:
33.8±3.2%).
Few allografted animals in each study group developed
acute rejection between days 21 and 150 post transplant, as
diagnosed by a sudden rise of serum creatinine and by
histological analysis of kidney graft taken from moribund
animals, showing interstitial cellular rejection with transplant
intimal arteritis, tubulointerstitial inflammation, and glome-
rulitis (not shown). For purpose of the present studies, we
have included in the analyses only data from all the
remaining animals that survived the 180-day follow-up and
developed CAI (Figure 1). None of the EPO-treated animals
died because of thrombosis or tumors, nor did they show
macroscopic signs of thrombosis or tumors at the time of
killing.
EPO prevents post-transplant anemia
Already at 7 days post-surgery, control untreated allografted
animals developed post-transplant anemia (Po0.05 vs. pre-
transplant, Figure 2a). It is interesting to note that also LW
rats receiving a syngeneic kidney graft had a decline (Po0.05
Figure 1 | Schematic representation of the experimental designs of Study 1, Study 2, and Study 3. *Evaluation of hemoglobin
and serum creatinine; wevaluation of proteinuria and blood pressure. mtime of killing; 1evaluation of albuminuria; Kday at which some
animals died before the end of the study. Control: untreated allografts of Study 1. Erythropoietin (EPO): EPO-treated allografts of Study 1.
Syngeneic: syngeneic grafts of Study 1. Control 2: untreated allograft of Study 2. Transfusion: blood transfusion–treated group of Study 2.
Control 3: untreated allograft of Study 3. WT: Wortmannin-treated group of Study 3. EPO3: EPO-treated allografts of Study 3. EPO/WT:
EPO plus Wortmannin-treated group. The number of animals of each group at the beginning and at the end of the study is shown in
parentheses. For Study 1, n¼ 3 rats in each group were killed at 21 days. i.m., intramuscular.
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vs. pre-transplant) of hemoglobin levels at 7 and 14 days post
transplant. Less EPO production following graft injury by
ischemia and surgery could explain the post-transplant
anemia in animals receiving either an allogeneic or a
syngeneic graft.28 EPO completely prevented post-transplant
anemia (Figure 2a).
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EPO treatment attenuates chronic graft dysfunction and
injury
Animals with syngeneic kidney grafts showed a mild,
progressive, age-related increase in blood pressure and
urinary protein excretion (Table 1 and Figure 2b).
Control allografted rats that completed the 180-day
follow-up developed CAI, with increase of blood pressure,
progressive proteinuria, and increase in serum creatinine.
Urinary protein excretion rate was consistent with the pattern
previously reported in the less severe Fisher-Lewis model,29
but proteinuria became significantly (Po0.05) higher than
baseline and was more severe at an earlier stage (60 days) post
transplant (Figure 2b). A progressive deterioration of renal
graft function was observed as documented by significant
(Po0.05) increase in serum creatinine over baseline starting
from day 120 post transplant (Figure 2). Graft histology at
the end of the 180-day follow-up showed tubular casts, severe
tubular injury and atrophy, interstitial inflammation, and
fibrosis (Figure 3a–d). Arteries had mild-to-moderate ob-
literative intimal fibrosis (score: 1.33±0.57). Severe glomer-
ular sclerosis and transplant glomerulopathy with double
contours of peripheral basement membranes were also found
(Figure 3a–d).
EPO protected from CAI. It did not modify blood
pressure, as compared with control rats (Table 1). In
EPO-treated animals, mean proteinuria values were signifi-
cantly lower (Po0.05) than that in controls from day
60 post transplant until the end of the study (Figure 2b).
EPO also prevented the increase in albuminuria observed
in control rats (Figure 2). The beneficial effect of EPO
did translate into better renal graft function. Indeed, at
150 days post transplant, serum creatinine levels were
significantly lower in the EPO than in the control group
(Figure 2).
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Figure 2 | Effect of erythropoietin (EPO) treatment on hemoglobin levels and renal function in animals of Study 1. Hemoglobin (Hb)
levels (a), 24-h proteinuria (b), 24-h albuminuria (c), and serum creatinine (d) in the three experimental groups of Study 1. Values are
mean±s.e.m. *Po0.05 vs. pre-transplant (analysis of variance (ANOVA) for repeated measures). wPo0.05 vs. control and zPo0.05 vs.
syngeneic (one-way ANOVA). For 24-h proteinuria and serum creatinine, statistical analysis was performed after log10 transformation of
data. Control: untreated allografts (n¼ 7). EPO: EPO-treated allografts (n¼ 6). Data are from animals that developed chronic allograft injury
and survived for 180 days. Syngeneic: syngeneic grafts (n¼ 9).
Table 1 | Systolic blood pressure (mmHg) in transplanted rats of Study 1
Time post transplant (day)
Groups Pre-transplant 30 60 90 120 150 180
Control (n=7) 121±5 134±19 145±14* 158±10*,*** 150±10* 143±9* 144±8*
EPO (n=6) 113±7 144±17*,** 142±10* 142±8* 138±7* 137±6* 136±5*
Syngeneic (n=9) 117±2 126±12 149±16* 144±8* 139±23* 140±21* 138±18*
Control: untreated allograft group; erythropoietin (EPO): allograft group treated with EPO.
Values are mean±s.d.
*Po0.05 vs. pre-transplant (analysis of variance (ANOVA) repeated measures).
**Po0.05 vs. syngeneic.
***Po0.05 vs. syngeneic and EPO (one-way ANOVA).
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EPO did also ameliorate renal lesions. After a 180-day
follow-up, in EPO animals, all tubulointerstitial changes
(Figure 3a and e) were significantly (Po0.05) lower than
those in controls. Mild arterial intimal thickening was
observed in EPO-treated grafts (mean score 1±0,
P¼nonsignificant vs. controls). Kidney grafts of EPO-treated
rats also showed strikingly less glomerular sclerosis and
transplant glomerulopathy than in control grafts (Po0.05;
Figure 3a–f).
A slight but significant decrease in synaptopodin and
nephrin glomerular staining was evident in untreated
allografts both at 21 and 180 days post transplant as
compared with syngeneic grafts and naive kidneys
(Po0.05, Figure 4). Glomerular nephrin staining was
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Figure 3 | Effect of erythropoietin (EPO) treatment on graft histology and apoptosis in animals of Study 1 surviving for 180 days.
Glomerular and tubulointerstitial injury (a and b) scores, percentage of tubular cell apoptosis (g), mRNA expression of Bcl-2 (h) and BAX (i)
in the grafts from animals of Study 1 surviving for 180 days. Control: untreated allografts (n¼ 7). EPO: EPO-treated allografts (n¼ 6).
Syngeneic: syngeneic grafts (n¼ 9). Values are mean±s.e.m. *Po0.05 vs. control; wPo0.05 vs. syngeneic (one-way analysis of variance).
(c–f) Representative micrographs of histological changes in renal allografts at 180 days. (c) Double contours in glomerular capillaries (arrows)
in untreated allograft; (d) untreated allograft; (e) EPO-treated allograft; (f) syngeneic graft. Original magnification in d–f:  200; original
magnification in c:  1000.
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significantly (Po0.05) higher in EPO-treated than in
untreated allografts, and retained a linear pattern similar to
the one found in syngeneic grafts (Figure 4). EPO treatment
also prevented the decrease of synaptopodin staining (Figure
4g), the disconnection of glomeruli from tubuli, and the
appearance of atrophic tubuli (Figure 3b).
In control allografts after the 180-day follow-up, sig-
nificantly higher numbers of macrophages, CD4þ and
CD8þ T cells, and major histocompatibility complex class
IIþ cells were found both in the renal interstitium and in the
periglomerular area than in syngeneic kidneys and in EPO-
treated allografts (Po0.05, Figure 5a and b, and Supplemen-
tary Figure S1 online). EPO treatment also significantly
prevented C4d and immunoglobulin G deposits in glomeruli
and C4d deposits on peritubular capillaries (Figure 5c and d).
Very few immunoglobulin G tubular deposits were found in
all groups.
We further studied tissue markers of oxidative stress, as
ischemic tissues and infiltrating macrophages express in-
ducible nitric oxide synthase (iNOS) and release reactive
oxygen species and N-derived oxidants,30,31 and oxidative
stress is involved in the pathogenesis of CAI.30–32
Already at 21 days post transplant, moderate iNOS and
nitrotyrosine stainings were observed in interstitial inflam-
matory cells, tubuli, and glomeruli both in control and EPO-
treated allografts (Table 2). At 180 days post transplant, iNOS
and nitrotyrosine stainings became moderate to intense in
control kidneys, whereas EPO-treated allografts showed
reduced renal oxidative stress with respect to control kidney,
and comparable to that observed in syngeneic grafts and
naive kidneys (Figure 6a–i, Table 2).
Correction of anemia per se is not enough to prevent CAI
To investigate whether correction of anemia per se could exert
a protective effect on CAI in our model, in Study 2
experiments we normalized post-transplant hemoglobin
levels by blood transfusions. As shown in Figure 7, all
parameters of CAI were comparable in transfused animals
and control untreated rats that developed post-transplant
anemia.
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We then moved to investigate the role of angiogenic and
cytoprotective actions of EPO in our model of CAI.
EPO prevents peritubular and glomerular capillary loss
As EPO has angiogenic effects,33 we evaluated whether the
protective effect of EPO on CAI was associated with
preservation of graft capillaries.34 Already at 21 days, in
control allografts of Study 1, we found a significant (Po0.05)
reduction in peritubular capillary (PTC) density area
(RECA-1þ ; Figure 8 and Supplementary Table S1 online)
and PTC length density (Lv) and volume density (Vv) as
compared with syngeneic grafts (Figure 8). The difference
was even more evident at 180 days (Figure 8, Supplementary
Table S1 online). EPO significantly prevented PTC loss in the
allografts both early (21 days) and late (180 days) post
transplant (Supplementary Table S1 online and Figure 8).
Glomerular RECA-1 staining in control and EPO-treated
grafts at 21 days was not different from isografts, whereas a
marked reduction of glomerular RECA-1þ area was observed
at 180 days in control but not in EPO-treated allografts
(Figure 8 and Supplementary Table S1 online).
We then analyzed the intragraft mRNA expression of
angiogenic factors. In control allografts studied 21 days post
transplant, vascular endothelial growth factor (VEGF) and
angiopoietin-1 expressions were comparable to syngeneic
grafts, whereas EGF expression was reduced (Table 3). EPO-
treated grafts had significantly (Po0.05) higher levels of
VEGF and EGF mRNA than control allografts (Table 3). At
180 days post transplant, VEGF, EGF, and angiopoietin-1
expression markedly reduced in control allografts (Table 3)
despite the hypoxic state of the allografts that should have
stimulated the expression of angiogenic factors. EPO
treatment preserved VEGF, EGF, and angiopoietin-1 expres-
sion levels to those observed in syngeneic grafts (Table 3).
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(one-way ANOVA).
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EPO prevents tubular apoptosis by activation of Akt
By terminal deoxytransferase uridine triphosphate nick end
labeling staining of Study 1 grafts, we found that CAI was
associated with marked tubular apoptosis, and that EPO
treatment completely prevented post-transplant tubular apop-
tosis (Figure 3). We then evaluated graft tissue staining for
activated Akt (p-Akt), a tyrosine kinase that functions as a
prosurvival antiapoptotic factor in renal tubular cells and is
Table 2 |Mean scores of inducible nitric oxide synthase (iNOS) and nitrotyrosine at 21 and 180 days post transplant in the
grafts of Study 1 animals
Glomerular score Tubular score Interstitial score
Groups iNOS Nitrotyrosine iNOS Nitrotyrosine iNOS Nitrotyrosine
Control
21 Days (n=3) 0.91±0.15 0.61±0.18 1.78±0.15 0.79±0.52 1.85±0.26**** 1.70±0.41****
180 Days (n=7) 1.52±0.14 2.45±0.17 1.96±0.08 1.23±0.59 1.98±0.37 1.75±0.32
EPO
21 Days (n=3) 0.83±0.19 0.52±0.21 1.10±0.13*** 0.82±0.43 1.79±0.22**** 1.65±0.28****
180 Days (n=6) 0.68±0.24* 0.82±0.27** 0.80±0.23* 0.18±0.21* 0.63±0.28***** 0.74±0.40*****
Syngeneic
21 Days (n=3) 0.77±0.21 0.25±0.18 0.95±0.17*** 0.51±0.23 0.25±0.25 0.31±0.18
180 Days (n=9) 0.82±0.15* 0.87±0.11** 0.98±0.24* 0.77±0.69 0.11±0.07***** 0.25±0.13*****
Naive
8 Months old (n=3) 0.40±0.20* 0.16±0.10**,****** 0.48±0.27* 0.05±0.09* 0.00±0.00*****,****** 0.00±0.00*****,******
Control: untreated allograft group; erythropoietin (EPO): EPO-treated allograft group; naive: untransplanted animals at 8 months of age. Each section was scored for intensity
(absent, faint, moderate, intense: 0 through 3). Values are mean±s.e.m.
*Po0.05 vs. control 180 days;
**Po0.001 vs. control 180 days;
***Po0.05 vs. control 21 days;
****Po0.01 vs. syngeneic 21 days;
*****Po0.01 vs. control 180 days;
******Po0.05 vs. EPO and syngeneic at 180 days (one-way analysis of variance).
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Figure 6 | Expression of inducible nitric oxide synthase (iNOS) and nitrotyrosine in the grafts of Study 1 animals surviving for 180
days. Representative images of immunostaining for iNOS (a–c) and nitrotyrosine (tubular staining: d–f; glomerular staining: g–i) in animals of
Study 1 surviving for 180 days. Control: untreated allografts (a, d, g). Erythropoietin (EPO): EPO-treated allografts (b, e, h). Syngeneic:
syngeneic grafts (c, f, i). Original magnification:  400.
910 Kidney International (2012) 81, 903–918
or ig ina l a r t i c l e P Cassis et al.: Erythropoietin in chronic allograft injury
activated by EPO through phosphorylation.10 As shown in
Figure 9a–g, we observed higher percentages of p-Aktþ tubuli
in EPO-treated allografts than in control allografts at 21 and
180 days post transplant. We also observed upregulation of
intragraft mRNA expression of the antiapoptotic molecule
Bcl-2 in EPO-treated rats as compared with grafts from
control rats, whereas expression of the proapoptotic BAX did
not differ in the two groups (Figure 3).
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Figure 7 | Effects of anemia correction on chronic allograft injury in animals of Study 2. (a) Hemoglobin (Hb) levels, (b) 24-h
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group of Study 2 (n¼ 10). Values are mean±s.e.m. *Po0.05 vs. pre-transplant (analysis of variance (ANOVA) for repeated measures).
wPo0.05 vs. control 2 (one-way ANOVA). For 24-h proteinuria and serum creatinine, statistical analysis was performed after log10
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We then investigated the role of Akt activation in the
renoprotective effects of EPO, by administering to allograft
recipients the inhibitor of Akt phosphorylation, Wortmannin
(WT), together with EPO (Study 3). WT partially but
significantly (Po0.01, EPO/WT vs. EPO3) blocked the EPO-
induced activation of tubular Akt in the allograft (Figure 9h),
and partially antagonized the protective effects of EPO on
renal graft function (Figure 10a), glomerular sclerosis,
tubular casts, apoptosis, nephrin and synaptopodin staining
(Figure 10b–e), and interstitial inflammatory cell infiltrate
(Figure 5). WT also completely antagonized the EPO effect of
upregulating Bcl-2 in the grafts, indicating that EPO-induced
Bcl-2 expression was downstream of p-Akt activation. No
effect of WT was observed on BAX levels (Figure 10f).
DISCUSSION
The present study shows that chronic treatment with EPO
limited tubulointerstitial and glomerular injury in a fully
a b c
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Figure 8 | Peritubular and glomerular capillary density in the grafts of Study 1 animals. (a–f) RECA-1 staining of peritubular capillaries
(a–c) and glomerular capillaries (d–f) at 21 days. Control: untreated allografts of Study 1 (n¼ 3; a, d). Erythropoietin (EPO): EPO-treated
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mismatched rat model of CAI, an effect that was associated
with preservation of peritubular capillaries and upregulation
of tubular p-AKT. Correction of anemia per se had no impact
on the signs of chronic graft injury and dysfunction. To the
best of our knowledge, this is the first evidence that long-
term administration of EPO is effective in preventing CAI in
kidney allografts.
In the kidney, the efferent glomerular arterioles enter the
PTC plexus, which surrounds tubuli and offers oxygen and
nutrients to tubular and interstitial cells. PTC and glomerular
capillary endothelium expresses major histocompatibility
complex I and II and is the primary renal graft component
that is targeted by the recipient immune system.35 Indeed,
during acute rejection, the common microscopic feature is a
pleomorphic interstitial infiltrate of cells that surrounds PTC
and glomerular capillaries, and evidence is available that PTC
inflammation and disruption occur in acutely rejecting
grafts.35 In miniature swine with CAI, a progressive decrease
in size and narrowing of the lumen of PTC and finally loss of
PTC in areas of interstitial inflammation and fibrosis have
been demonstrated.36 Similarly, in human CAI, the number
and the area of PTC in the renal cortex were reduced as
compared with pre-transplant graft biopsies, accompanied by
progression of interstitial fibrosis and rise in serum
creatinine.35 It is noteworthy that PTC lesions often preceded
glomerular lesions.35 This scenario of tubulointerstitial injury
well applies to our rat model of CAI, in which post-
transplant PTC loss, peritubular inflammation, and tubular
injury were found.
Under hypoxic conditions, mitochondrial dysfunction
occurs in renal tubular cells, which leads to uncontrolled
production of reactive oxygen species.37 Oxidative stress is a
possible cause of tubulointerstitial injury in CAI, as
documented by present and published experimental and
clinical data30–32 showing intense tubular nitrotyrosine and
iNOS immunostaining in chronic kidney transplant failure.
Anemia, by lowering hemoglobin concentration and
ultimately the amount of oxygen delivered to the kidney,
could synergize with PTC loss in inducing chronic tubu-
lointerstitial hypoxia.7 Although we did not measure oxygen
content in the graft, it is reasonable to speculate that EPO
treatment could have contributed to increased oxygen
delivery to the tubulointerstitial area at dual level, by
correcting post-transplant anemia and by preserving PTC
number.
However, the finding that correction of anemia alone by
blood transfusions did not prevent graft injury indicates that
the protective effects of EPO documented in allografted rats
should go beyond correction of anemia.
EPO has paracrine activity mediated through EPO
receptors in various organs, including the kidney,38 and here
we confirm the presence of EPO receptors in glomeruli and
tubuli of both naı¨ve and transplanted rat kidneys (Supple-
mentary Figure S2 online). EPO exerts direct vascular
protection through inhibition of apoptotic cell death–related
pathways,10,20,21 stimulation of regenerative endothelial
progenitor cell recruitment,33 and proangiogenic actions.39
In endothelial and epithelial cells, EPO stimulates the
production of angiogenic factors either directly40,41 or
indirectly by increasing the expression of hypoxia-inducible
factor-1alpha.42 Intra-graft expression of VEGF, EGF, and
angiopoietin-1—another angiogenic factor highly expressed
in the kidney43 and essential for vascular remodeling and
maintenance of vascular integrity44—are downregulated in
CAI (45,46, present data). Such reduction is likely due to the
profound injury of vascular endothelial cells in the graft late
post transplant. It is noteworthy that we found that EPO
treatment maintained intra-graft expression of these angio-
genic factors to levels very comparable to those found in
syngeneic grafts, which may have contributed to preserve
PTC density.
There is also evidence that EPO exerts direct cytoprotec-
tion of tubular cells against inflammatory and ischemic
injury both in vitro and in vivo,47,48 through the interaction
with the non-erythropoietic heterodimeric EPOR-bcR
receptor.49 In rats with extensive renal mass reduction, a
dose of EPO low enough not to modify the hematocrit level
was, however, protective from progressive renal function
deterioration, an effect that was associated with activation of
the pro-survival Akt tyrosine kinase in renal endothelial and
epithelial cells.10 Finding tubular Akt activation and upregu-
lation of the antiapoptotic molecule Bcl-2 in EPO-treated
allografts indicate that p-Akt-mediated cytoprotective prop-
erties of EPO on tubular cells had some role in attenuating
Table 3 | VEGF, EGF and angiopoietin-1 mRNA expression (arbitrary units) in the grafts of Study 1 animals
VEGF EGF Angiopoietin-1
Groups 21 Days 180 Days 21 Days 180 Days 21 Days 180 Days
Control 1.35±0.06* 0.25±0.07 0.59±0.48* 0.02±0.01 2.62±0.34* 0.88±0.22
EPO 1.90±0.36** 0.69±0.58* 1.28±0.21** 0.58±0.51* 1.87±0.23 2.07±1.03*
Syngeneic 1.10±0.15 0.99±0.39* 1.01±0.22** 0.63±0.49* 2.53±1.13 2.53±1.13*
Abbreviations: EGF, endothelial growth factor; EPO, erythropoietin; VEGF, vascular endothelial growth factor.
Control: untreated allograft group (21 days, n=3; 180 days, n=7); EPO: EPO-treated allograft group (21 days, n=3; 180 days, n=6). The mRNA analysis was performed by real-
time polymerase chain reaction. The complementary DNA contents in each sample was calculated by DDCt. Calibrator (naive Wistar Furth kidney, n=3) was set to 1. Data are
mean±s.e.m.
*Po0.05 vs. control at 180 days.
**Po0.05 vs. control at 21 days (one-way analysis of variance).
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tubulointerstitial injury. Inhibition of p-Akt phosphorylation
with Wortmannin partially antagonized the antiapoptotic
and renoprotective properties of EPO, although because of
low numerosity this finding cannot be considered definitive.
Further ad hoc designed studies are required to definitely
establish the actual role of p-Akt upregulation in mediating
the protective effect of EPO against CAI.
Unexpectedly, animals given Wortmannin alone were
protected from CAI. Notably, we found that Wortmannin
significantly prevented the intragraft increase of interleukin
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Control 3: untreated allograft group; EPO3: allograft group treated with EPO; WT: 
allograft group treated with Wortmannin; EPO/WT: allograft group treated with EPO 
and Wortmannin. Each section was scored as % of p-Akt+ tubuli/total tubuli. Values 
are mean ± S.E.M., *P < 0.01 vs. control 3; †P < 0.01 vs. EPO3 (one-way ANOVA).
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Figure 9 | Expression of p-AKT in the grafts of Study 1 and Study 3 animals. (a–f) Immunostaining analysis for phosphorylated Akt
(p-Akt) in tubuli of animals killed at 21 days (a, b, c) of Study 1 or surviving for 180 days (d–f) of Study 1. P-Akt in red, lectin in green, and
merge in yellow. Control: untreated allografts. Erythropoietin (EPO): EPO-treated allografts. Syngeneic: syngeneic grafts. Original
magnification:  400. (g and h) Mean percentages of p-Aktþ tubuli (g, Study 1; h, Study 3).
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(IL)-2 mRNA levels that instead occurred in untreated controls
(Supplementary Table S2 online). In preliminary experiments
(Supplementary Figure S3 online), we found that naive LW
rats treated with Wortmannin displayed reduced T-cell
alloreactivity against WF antigens in vitro, suggesting that
Wortmannin could have exerted some immunosuppressive
effect in our model. These results are in line with previous
studies showing that Akt has a role in T-cell development50
and in translating intracellularly the activation signals triggered
by T-cell receptor and costimulatory molecules.51
The pathogenesis of glomerular injury in CAI is still a
matter of investigation; however, available data indicate that
both immune mechanisms, by cellular and antibody-
mediated components,52,53 and hemodynamic changes due
to capillary loss35,54 may have a role. All the above events
have been implicated as important contributors to glomer-
ular capillary injury,40,55,56 which determines podocyte
dysfunction and loss,57,58 and consequently an exuberant
traffic of proteins through the glomerular capillary barrier.
Consistent with these findings, we found high numbers of
inflammatory cells and intense immunoglobulin G and C4d
staining in the glomeruli of untreated allografts that
developed CAI, and intense iNOS and nitrotyrosine im-
munostaining, which were paralleled by reduction of nephrin
and synaptopodin staining. Reduction of nephrin and
synaptopodin staining in CAI could be caused by inflamma-
tory cytokine released by infiltrating macrophages; alterna-
tively, it might reflect podocyte loss.59 EPO treatment
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Figure 10 | Effect of Wortmannin on chronic allograft injury in animals of Study 3. Serum creatinine (a), tubulointerstitial and
glomerular injury scores (b and c), scores for nephrin and synaptopodin glomerular stainings (d), percentage of tubular cell apoptosis (e),
mRNA expression of Bcl-2 and BAX (f) in animals of Study 3 surviving for 180 days. Values are mean±s.e.m. *Po0.05 vs. control 3; wPo0.05
vs. EPO3; zPo0.05 vs. EPO/WT (one-way analysis of variance (ANOVA)). 1Po0.05 vs. pre-transplant (ANOVA repeated measures). For serum
creatinine, statistical analysis was performed after log10 transformation of data. Control 3: untreated allograft of Study 3 (n¼ 3). WT:
Wortmannin-treated group of Study 3 (n¼ 3). EPO3: EPO-treated allografts of Study 3 (n¼ 4). EPO/WT: EPO plus Wortmannin-treated group
(n¼ 4).
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protected glomerular cells from inflammatory cell infiltration
and oxidative stress injury, and largely prevented podocyte
abnormalities. These data are in agreement with previous
observations that the cytoprotective effect of EPO not only
relates to its antiapoptotic20,21 and angiogenic activities,10 but
also involves its anti-inflammatory and antioxidant
properties.10,60 Podocytes express EPO receptors, and EPO
has been shown to protect podocytes from apoptosis in a
model of antiglomerular antibody–induced glomerulonephri-
tis via Akt signaling.21 However, in this study, the finding
that EPO did not modify podocyte Akt phosphorylation
in the allografts would not support a direct cytoprotective
effect of EPO on podocytes in our model (Supplementary
Table S3 online).
In conclusion, we have documented that EPO largely
protects rats from tubulointerstitial injury by upregulating
the expression of angiogenic factors and preserving PTC
number and by protecting tubular cells from apoptosis
through activation of the survival factor Akt. These effects
translate into less glomerular insult, limited production of
reactive oxygen species, and preservation of podocyte
structure and function. The present findings highlight a
new example of the pleiotropic effect of EPO well beyond the
maintenance of red blood cell mass, and should prove useful
in the development of novel therapeutic and/or preventive
measures for CAI in the clinical setting.
Clinical trials aimed to correct anemia with EPO in
transplanted patients showed that increasing hemoglobin to
above 14 g/dl is associated with an increase in cardiovascular
events and mortality.61 Direct toxicity of high EPO doses,
alteration of blood viscosity, and increased platelet function
have all been postulated as possible causes of increased
morbidity and mortality.61–63 The results presented here
suggest that non-erythropoietic derivatives of EPO under
development63 could be useful to prevent CAI in renal
transplant patients while avoiding the side effects of EPO on
blood viscosity and platelet function.
MATERIALS AND METHODS
Animals
Inbred WF and LW rats weighing 210–250 g were used (Charles
River, Calco, Italy). Procedures involving animals and their care were
conducted in accordance with the institutional guidelines in
compliance with national and international laws and policies.25
Erythropoietin dosing
We evaluated the most appropriate EPO regimen to prevent anemia
early post transplant. Given the immunogenicity of recombinant
human EPO when administered chronically to rats,64 we used
mouse EPO (EPO, 200 IU/mg; Amgen, Thousand Oaks, CA). We
found that 10 mg/kg mouse EPO given subcutaneously on the day of
transplant (EPO10) to LW rats receiving a WF allogeneic transplant
(n¼ 6), followed by 2.5 mg/kg weekly, failed to prevent hemoglobin
decline at day 7 and 14 post transplant (Supplementary Table S4
online), whereas post-transplant anemia was completely prevented
by a loading dose of 30 mg/kg, followed by 2.5 mg/kg weekly. Thus,
the latter regimen was used in subsequent experiments.
Renal histology and immunohistochemistry
Dubosq-Brazil–fixed sections were used for histological examina-
tions. Frozen sections were used for ED1, OX6, CD8, CD4,
nitrotyrosine, nephrin, C4d, immunoglobulin G, RECA-1, p-Akt,
EPO-R, nestin, and synaptopodin staining. Paraffin-embedded
sections were used for terminal deoxytransferase uridine triphos-
phate nick end labeling and iNOS staining. Detailed methods and
list of antibodies are provided in Supplementary Methods online.
Real-time polymerase chain reaction
Primers and detailed methods for real-time polymerase chain
reaction are provided in Supplementary Methods online.
Statistical analysis
Results are mean±s.e.m. The significance of differences between
individual groups was analyzed by one-way analysis of variance,
post-hoc Student–Newman–Keuls test. For blood pressure, protei-
nuria, and serum creatinine, changes of the parameters over time
were evaluated by analysis of variance for repeated measures, post-
hoc Fisher protected least significant difference test. For proteinuria
and serum creatinine, statistical analysis was performed after log10
transformation of data, because of the variability of the data within
each group.
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